ArticleJHEP reports : innovation in hepatology2025
An engineered human hepatitis A virus capable of rapid proliferation
Article in JHEP reports : innovation in hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advances and perspectives in animal models of human hepatitis A virus.Animal models and experimental medicine · 2026Review
- Host species-specific mutations in the thumb domain of the 3Dpol polymerase are required for efficient replication of human hepatitis A virus in mice.PLoS pathogens · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: Hepatitis A virus (HAV) remains a significant public health threat. The HM175-mp4-based mouse model has advanced pathogenesis research, but its slow Methods: Two cell-adaptive substitutions, A1052V in the 2B protein and F1163S in the 2C protein, were introduced into HM175-mp4 to generate the recombinant HAV-2m virus. HAV-2m was propagated in Huh7.5.1 cells and intravenously injected into Results: HAV-2m replicated effectively Conclusion: The HAV-2m reverse genetic system and its mouse model provide a tractable platform for dissecting HAV pathogenesis and evaluating antiviral strategies. Impact and implications: Hepatitis A virus (HAV) is an ongoing public health concern, yet experimental tools to study recombinant HAV mutants remain limited. We developed a genetically tractable recombinant virus (HAV-2m) that replicates efficiently in cell culture, induces acute hepatitis in mice, and revealed a novel virulence determinant in the viral 2C protein. This platform enables detailed dissection of HAV pathogenesis and the evaluation of antiviral countermeasures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.